Rajesh Patel
Business Head,
Agappe Diagnostics Ltd.

Hematology instruments and reagents market in India

Hematology is one the major segments in the IVD market in India, which is estimated at more than Rs 1000 crore in the year 2019. The segment is controlled by 3-part hematology analyzers and its corresponding reagents with a market share of ~65 percent, and the remaining market is controlled by 5-part hematology analyzers. It is estimated that more than 11,000 units of 3-part hematology analyzers are installed in India in 2019, followed by 3000 units of 5-part hematology analyzers.

Out of the existing more than 55,000 laboratories in India, more than 40,000 laboratories are in the Tier-II and Tier-III segments, covering the rural and semi-urban population with limited access to majority of IVD technologies. As per statistics, more than 70 percent of the Indian population lives in the rural area, and the benefits of IVD technologies remain underserved to the patients in these rural areas. One of the major changes in the hematology segment is the introduction of highly compact 3-part and 5-part hematology systems. These compact systems are well suited for the rural India, and are expected to bring in changes in the IVD industry. The penetration of CBC in rural areas will help to assess the prevalence of various anemia (which is one of the major concerns in India) among the rural population and its control, which is an objective of the NRHM, and an affordable and accurate 3-part hematology analyzer is the need of the hour. The hematology market in India is dependent only on import – the major suppliers being from China, Europe, Japan, and USA. The current inflation in the forex rates is one of the major concerns in the Indian hematology segment. The recent pandemic of COVID-19 has created a huge demand in hematology testing where a low WBC count, along with a decreased lymphocyte count, is of importance in the early stages of the disease, further adding to our woes on cost of testing.

Truly indigenous hematology systems are in the pipeline with state-of-the-art technology to suite the Indian scenario, and these are expected to hit the market in the coming months. It is believed that with local manufacturing both the hardware and consumable cost of CBC testing will be reduced drastically, and it will bring down the dependency of our country on imports. This India’s truly first indigenously developed and manufactured 3-part hematology analyzer will change the overall market of hematology, which is long awaited since more than five decades.

Share this:
Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.